Kabra Drugs Ltd Financials
Company Logo

Kabra Drugs Ltd Financial Statement

Kabra Drugs Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
RevenueTBA
Operating Expense0.40
Net Profit-0.40
Net Profit MarginTBA
Earning Per Share-0.39
EBIDTA-0.40
Effective Tax RateTBA
Invest in Kabra Drugs Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Kabra Drugs Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.74
Operating Profit Annual-0.74
Interest AnnualTBA
DepreciationTBA
Net Profit Annual-0.74
Tax AnnualTBA

Kabra Drugs Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the BeginningTBA
Cash Flow from Operations-0.21
Cash Flow from InvestingTBA
Cash Flow from Financing2.88
Cash Flow at the End2.67

Kabra Drugs Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)TBA
Total Debt / Equity (X)8.83
Asset Turnover Ratio (%)TBA

Kabra Drugs Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets AnnualTBA
Total Current Assets Annual4.55
Non Current Assets Annual0.02
Total Shareholders Funds Annual1.08
Total Assets Annual4.57

Kabra Drugs Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Dec 3, 2024, Kabra Drugs Ltd has a market capitalization of 3.16 Cr. Value Research classifies it as a Micro-Cap company.
No, Kabra Drugs Ltd is not debt-free with a debt-to-equity ratio of 1.58.
In FY 2023 , Kabra Drugs Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Kabra Drugs Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.2% and NaN% annually, respectively..
Kabra Drugs Ltd's current PE ratio is -4.27.
Kabra Drugs Ltd's ROCE averaged -35.9% from the FY ending March 2022 to 2024, with a median of -29.3%. It peaked at -26.4% in March 2024, reflecting strong capital efficiency over the period..
Kabra Drugs Ltd's latest EBIT is Rs. -0.74 Cr, surpassing the average EBIT of Rs. -0.42 Cr over the 5 years..